Kangai Jingfang is a traditional Chinese medicine formula, also referred to as Anticancer Essence Formula, that is being investigated for its therapeutic potential in treating advanced colorectal cancer. It is specifically studied for stage III - IV colorectal cancer characterized by spleen deficiency and essence deficiency types. The drug is administered orally.
Other names
Anticancer Essence Formula抗癌精方口服
02
Targets
AR (Adrenergic receptors)EGFR (Epidermal growth factor receptor)ESR1 (ERα)HDAC1 (Histone Deacetylase 1)HSP90AA1 (Heat shock protein HSP90-alpha)MMP9 (Matrix metalloproteinase-9)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)STAT3 (Signal Transducer and Activator of Transcription 3)TNFR2/PI3K/AKT/NF-κB (Tumor necrosis factor receptor 2/Phosphoinositide 3-kinase/Protein kinase B/Nuclear factor kappa-light-chain-enhancer of activated B cells signaling axis)TP53 (Cellular Tumor Antigen p53 R175H)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on Kangai Jingfang.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from study design and recruitment through results.
Trial phase
Status
Readouts
Indications & development
Explore development by indication, patient population, and geography.
Indications
Development status
Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
Partners
Deal terms
Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
Patents
Expiration dates
Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
Competing assets
Targets
Development stage
Research & analysis
Connect source evidence and development news to your research questions.
Publications
News
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kangai Jingfang.